Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
1(20.0%)
Early Phase 1
1(20.0%)
5Total
Phase 2(3)
Phase 1(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05505747Phase 2Withdrawn

Enhancing Recovery Through a Combined Mechanobiologic Intervention Following Meniscus Repair

Role: lead

NCT04572256Early Phase 1Recruiting

MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

Role: lead

NCT05149287Phase 2Terminated

PROPER Trial of Pain and Inflammation After Knee Arthroscopy

Role: lead

NCT04331002Phase 2Terminated

Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury

Role: lead

NCT04770064Phase 1Withdrawn

Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)

Role: lead

All 5 trials loaded